Shares of AVROBIO, Inc. (NASDAQ:AVRO) have been assigned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.40.
AVRO has been the topic of a number of recent research reports. Morgan Stanley cut their target price on AVROBIO from $31.00 to $29.00 and set an “overweight” rating on the stock in a research note on Friday, July 16th. BTIG Research reiterated a “buy” rating and issued a $23.00 target price on shares of AVROBIO in a research note on Friday, August 6th. Needham & Company LLC initiated coverage on AVROBIO in a research note on Thursday, May 27th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Zacks Investment Research upgraded AVROBIO from a “sell” rating to a “hold” rating in a research note on Monday, September 6th.
In related news, Director Philip J. Vickers purchased 4,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 7th. The shares were purchased at an average price of $8.35 per share, with a total value of $40,080.00. Following the purchase, the director now owns 4,800 shares of the company’s stock, valued at approximately $40,080. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.
Shares of AVRO opened at $6.22 on Tuesday. The business’s fifty day moving average price is $6.72 and its 200 day moving average price is $9.05. AVROBIO has a 12-month low of $5.44 and a 12-month high of $20.07. The stock has a market capitalization of $271.34 million, a PE ratio of -1.99 and a beta of 1.34.
AVROBIO (NASDAQ:AVRO) last announced its quarterly earnings data on Wednesday, August 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.08). Sell-side analysts predict that AVROBIO will post -2.86 EPS for the current year.
AVROBIO Company Profile
Avrobio, Inc engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis.
Recommended Story: What is a trade deficit?
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.